Start Over

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.

Authors :: Martinez DR
Schäfer A
Leist SR
Li D
Gully K
Yount B
Feng JY
Bunyan E
Porter DP
Cihlar T
Montgomery SA
Haynes BF
Baric RS
Nussenzweig MC
Sheahan TP
Source :: Cell reports [Cell Rep] 2021 Jul 27; Vol. 36 (4), pp. 109450. Date of Electronic Publication: 2021 Jul 10.
Publication Year :: 2021
Abstract: Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants.<br />Competing Interests: Declaration of interests J.Y.F., E.B., D.P.P., and T.C. are employed by Gilead Sciences Inc.<br /> (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)